Related Experiment Video
Updated: Aug 23, 2025

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Hormonal Approach for Postmenopausal Vulvovaginal Atrophy
Ana Paula Ferreira Costa1, Ayane Cristine Alves Sarmento1, Pedro Vieira-Baptista2,3
1Health Sciences Postgraduate Program, Federal University of Rio Grande do Norte (UFRN), Natal, Brazil.
Hormone therapy (HT) is the most effective treatment for urogenital atrophy symptoms like dryness and irritation, even with potential side effects. Treatment should be individualized based on menopausal stage.
Area of Science:
- Gynecology and Reproductive Medicine
- Menopause and Aging
- Urogynecology
Background:
- Menopause involves decreased ovarian reserve, leading to hypoestrogenic conditions affecting the genital tract.
- Vulvovaginal atrophy (VVA) presents with symptoms like dryness, burning, irritation, and urinary issues, impacting both postmenopausal and some premenopausal women.
Purpose of the Study:
- To provide an updated review of hormone therapy (HT) for urogenital atrophy, encompassing local and systemic treatments.
- To emphasize the clinical significance of understanding and actively managing VVA.
Main Methods:
- Review of current literature on hormone therapy for urogenital atrophy.
- Discussion of local and systemic hormone therapy options.
- Analysis of the efficacy and side effects of hormone therapy.
Main Results:
- Hormone therapy remains the most effective treatment for alleviating symptoms of urogenital atrophy.
- Individualized treatment plans are crucial, considering the woman's menopausal stage (perimenopausal, postmenopausal).
Conclusions:
- Active management and treatment of urogenital atrophy are essential for improving women's quality of life.
- Hormone therapy, when used judiciously and tailored to individual needs, is the primary therapeutic choice for VVA symptoms.
More Related Videos
14:26A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
Published on: April 7, 2014
11:53Laparoscopic Oocyte Retrieval and Cryopreservation during Vaginoplasty for Treatment of Mayer-Rokitansky-Kuster-Hauser Syndrome
Published on: May 10, 2022
Related Concept Videos
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Menopause
Hormonal Regulation
Vagina
Disorders of the Female Reproductive System